You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel Inhibitors of Pim Protein Kinases

    SBC: VORTEX BIOTECHNOLOGY CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): There is a growing body of evidence that implicates the protein kinase Pim-1 as a major driver of prostate cancer progression, and perhaps response to chemotherapy. Pim-1 is overexpressed in early prostate intraepithelial neoplasia and metastatic prostate cancer, and its levels predict response to therapy. Pim-1-overexpressing mouse prostate stem cells demonstr ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  2. Snapshot Raman Spectral Imager

    SBC: Applied Quantum Technologies            Topic: A09AT009

    Applied Quantum Technologies along with its university partner Duke University propose a coded-aperture, multi-aperture snapshot Raman imager. By combining an innovative optical design and advanced compressed sensing algorithms, a snapshot system provides dwell times much shorter than conventional slit-based or tunable-filter based spectral imagers. A short-wave infrared excitation source allows f ...

    STTR Phase I 2009 Department of DefenseDefense Advanced Research Projects Agency
  3. Development of Lysosomal Modulatory Drugs to Treat Alzheimer's Disease

    SBC: SYNAPTIC DYNAMICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Reducing protein deposition events is essential for slowing the progression of Alzheimer's disease (AD), especially A 1-42 peptide oligomers that accumulate inside and outside neurons and cause functional compromise. Finding a strategy to reduce A oligomeric assemblies is widely thought to be the key objective for treating AD. Accumulation of A peptides is on ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  4. Acid Ceramidase, Target for Cancer

    SBC: Sphingogene, Inc            Topic: N/A

    DESCRIPTION (provided by applicant): Acid ceramidase (AC) has been implicated as a novel target for cancer therapy because of its pivotal role in regulating interconversion of three key bioactive lipids; ceramide (Cer), sphingosine (Sph) and Sphingosine-1-Phosphate (S1P). It is well known that Cer functions predominantly as a tumor suppressor lipid and mediator of apoptosis following chemo and rad ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  5. Functional Tissue Engineering for Cartilage Repair

    SBC: Cytex Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Degenerative joint diseases such as osteoarthritis remain the source of significant pain and disability, affecting 20 million adults with an economic burden of over 40 billion per year to the United States. While joint replacement is a well-established procedure, its finite life span makes this treatment unacceptable for younger or more active individuals, of ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  6. Development of ADAM10 Prodomain as a Therapeutic Agent

    SBC: BIOZYME, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Recent cancer therapies have focused on using biologics to target specific signal transduction pathways implicated in the tumor development or progression. For example, recombinant fusion proteins consisting of the extracellular domain of the immunoregluatory proteins and the constant (Fc) domain of immunoglobulin (IgG) represent a growing class of protein ther ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  7. Prevention Buffet: An Internet Prevention Resource for Middle Schools

    SBC: TANGLEWOOD RESEARCH INC            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this STTR Phase I proposal is to develop a searchable Internet database of prevention lessons called Prevention Buffet. The database will allow middle school teachers to customize prevention efforts in their classrooms to the needs of their students, while providing them with guidance in selecting and implementing prevention lessons. Lessons will be ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  8. NF-kB Inhibition of Lung Ischemia Repurfusion Injury

    SBC: THERALOGICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Ischemia-reperfusion injury (IRI) is a major problem in many clinical scenarios, including myocardial infarction and stroke. IRI is also a major problem in organ transplantation, because IRI is the major cause of primary graft failure and organ dysfunction after transplant. Increasingly, graft injury due to IRI at the time of implantation is recognized as a maj ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  9. Data-Parallel Analytics on Graphics Processing Units (GPUs)

    SBC: SYSTAP, LLC            Topic: ST13B004

    The proposed effort will extend existing proofs of concept and advanced research systems to: (a) provide an efficient, low-level, data-parallel runtime for graph processing on GPUs; (b) provide a high-level abstraction for writing graph analytics that are

    STTR Phase I 2014 Department of DefenseDefense Advanced Research Projects Agency
  10. New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cyto

    SBC: Nirvana Sciences, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Polychromatic flow cytometry [FC] is one of the most powerful analytical techniques routinely used in immunology. Flow cytometry plays a critical role in several growing clinical applications: leukemia and lymphoma immunophenotyping for diagnosis and sub-categorization (now using 8-10 colors); in CD4/CD8 measurement in HIV-positive patients; and in HLA typing f ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government